Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Differences in Plaque Progression Depending on its Characteristics

The pattern of growth for each plaque differs according to the presence of certain risk factors. Atheroma volume at baseline was the most important predictor of plaque developing into obstructive lesions, as opposed to other characteristics historically considered as “dangerous.”

iFR en lesiones no culpables: el momento de la medición parece cambiar la historia

The aim of this study was to analyze whether the pattern of non-obstructive lesion progression could differ according to certain characteristics.

It is still debatable whether such characteristics simply represent a different phase during the natural history of the disease or if they can anticipate disease progression.

This prospective, multinational registry enrolled consecutive patients with non-obstructive coronary artery lesions (<50%), who underwent serial coronary computed tomography angiography at intervals at least 2 years.

High-risk plaque was defined as lesions with 2 or more of the following features: positive remodeling, calcified nodules, and hypoattenuation. Baseline quantitative angiographic percent obstruction and atheroma volume were compared over time between high-risk and non-high-risk plaque.


Read also: Subintimal Re-Entry in CTO Improves Outcomes.


A total of 3049 non-obstructive lesions were identified in 1297 patients (mean age 60.3 ± 9.3 years); 425 lesions met the high-risk criteria and 2624 did not.

Upon adjusted multivariate analysis, only baseline atheroma volume and obstruction percentage could independently predict plaque progression (p < 0.05 for both). High-risk characteristics were not associated with progression over time.

Conclusion

Each non-obstructive plaque has its own individual morphologic pattern, and only baseline atheroma volume and obstruction percentage could predict their progression over time. High-risk characteristics could not predict progression, even when considered as a composite.

Original title: Differences in Progression to Obstructive Lesions per High-Risk Plaque Features and Plaque Volumes With CCTA.

Reference: Sang-Eun Lee et al. JACC Cardiovasc Imaging. 2020 Jun;13(6):1409-1417. doi: 10.1016/j.jcmg.2019.09.011.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...